These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34638370)

  • 1. A Modified Intraperitoneal Chemotherapy Regimen for Ovarian Cancer: Technique and Treatment Outcomes.
    Kim JH; Ha HI; Kim MH; Han MR; Park SY; Lim MC
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.
    Seamon LG; Carlson MJ; Richardson DL; Cohn DE; Fowler JM; Copeland LJ; O'Malley DM
    Int J Gynecol Cancer; 2009 Oct; 19(7):1195-8. PubMed ID: 19823054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
    Oaknin A; Roda D; González-Martín A; Chiva L; García-Donas J; de Juan A; Redondo A; Martínez S; García Y; Catot S; Ponce J; Del Campo JM; Cervantes A; Poveda A
    Int J Gynecol Cancer; 2011 Aug; 21(6):1048-55. PubMed ID: 21738038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.
    Becker DA; Leath CA; Walters-Haygood CL; Smith BQ; Bevis KS
    Am J Clin Oncol; 2019 Jan; 42(1):12-16. PubMed ID: 29782365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer.
    Chambers LM; Son J; Radeva M; DeBernardo R
    J Gynecol Oncol; 2019 Nov; 30(6):e93. PubMed ID: 31576687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer.
    Meghal T; Dave V; Tang H; Kumar V; Xu Y
    World J Clin Oncol; 2019 May; 10(5):201-212. PubMed ID: 31205865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications.
    Lesnock JL; Richard SD; Zorn KK; Krivak TC; Beriwal S; Sukumvanich P; McBee WC; Kelley JL; Edwards RP
    Gynecol Oncol; 2010 Mar; 116(3):345-50. PubMed ID: 19959211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of grade 3/4 toxicity associated with intraperitoneal chemotherapy administered after primary versus interval surgical debulking in ovarian cancer.
    Le T; Latifah H; Jolicoeur L; Faught W; Weberpals J; Hopkins L; Fung-Kee-Fung M
    Int J Gynecol Cancer; 2011 Jul; 21(5):811-5. PubMed ID: 21412160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
    Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
    Bruixola G; Domingo S; Díaz R; Caballero J; Palomar L; De La Cueva H; Santaballa A
    Int J Gynecol Cancer; 2015 Feb; 25(2):214-21. PubMed ID: 25415075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer.
    Battelli C; Campo M; Buss MK; Awtrey CS; Konstantinopoulos PA
    Chemotherapy; 2013; 59(4):251-9. PubMed ID: 24457572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
    Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.
    Lee J; Curtin JP; Muggia FM; Pothuri B; Boyd LR; Blank SV
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):55-63. PubMed ID: 29704010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients.
    Koo YJ; Lim KT
    Taiwan J Obstet Gynecol; 2015 Jun; 54(3):275-9. PubMed ID: 26166340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
    Ballesta-López O; Albert-Marí A; Borrell-García C; Melián-Sosa M; Salvador-Coloma C; Santaballa-Bertrán A; Poveda-Andrés JL
    J Oncol Pharm Pract; 2021 Mar; 27(2):268-278. PubMed ID: 32279599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal treatment for advanced ovarian cancer, the Dutch experience. What did we learn?
    Rietveld MJA; van der Velden J; Westermann AM; van Driel WJ; Sonke GS; Witteveen PO; Ploos van Amstel FK; Massuger LFAG; Ottevanger PB
    Neth J Med; 2020 Dec; 78(6):349-356. PubMed ID: 33380532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.